SGLT2isodium–glucose co-transporter 2 inhibitorsCardiometabolic diseasechronic kidney diseasetype 2 diabetes mellitusheart failureSheffield Centre for Health and Related Research
…acist-led review. Overall, 32/75 patients (43%) were started on SGLT2i therapy according to guideline criteria. In the exploratory sub…